

Does the choice of independent expert committee affect ICER outcomes?

Beenish Majeed, Richard Macaulay & Michael Tang
Parexel International,
London, UK
richard.macaulay@parexel.com

Background

- The Institute for Clinical and Economic Review (ICER) publishes reports on the clinical and economic value of drugs for US payers.
- Each report is subject to a public meeting by one of three independent expert committees that discusses the report and votes on the evidence presented:
 - California Technology Assessment Forum (CTAF)
 - Midwest Comparative Effectiveness Public Advisory Council (CEPAC)
 - New England CEPAC
- This research compares and contrasts outcomes by committee.

Methods


- All publicly-available final ICER reports of pharmaceuticals (01/01/2014-12/31/2019) were screened and key data extracted.

Results

- 38 ICER reports of pharmaceuticals were identified (CTAF: 11; Midwest CEPAC: 12; New England CEPAC: 15), encompassing 110 drugs in 78 conditions/subgroups.


Clinical ratings

- Clinical ratings were provided for 277 drug comparisons (CTAF: 41; Midwest CEPAC: 46; New England CEPAC: 190).
 - For the CTAF, Midwest CEPAC, New England CEPAC, respectively, 19 (46%), 23 (50%), and 33 (17%) drug comparisons achieved a rating of A, B, or B+; 3 (7%), 9 (20%), and 80 (42%) achieved a rating of C, C+, C-, or D; 19 (46%), 14 (30%), and 77 (41%) achieved a rating of P/I or I.




Cost-utility assessments

- Cost-utility assessments were undertaken for 117 treatment settings (CTAF: 35; Midwest CEPAC: 32; New England CEPAC: 50).
 - At a willingness-to-pay threshold of \$150,000/QALY, 11 therapies (31%) were deemed cost-effective/cost-saving by the CTAF, 9 (28%) by the Midwest CEPAC, and 21 (42%) by the New England CEPAC.



Healthcare value

- Of the 51 votes for healthcare value, most drugs had a majority vote of low or intermediate value:
 - CTAF: 9 (90%); Midwest CEPAC: 12 (86%); New England CEPAC: 22 (81%).



Conclusion

- There are generally few differences between ICER committee outcomes, although there are some variances, which are likely due to therapy area focus.
- Considering healthcare value, ICER committees are generally consistent in reporting that most drugs provide low to intermediate value.